Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999 Sep 2. 341(10):738-46. [QxMD MEDLINE Link].
Choudhury P, Chen W, Hunt RC. Production of platelet-derived growth factor by interleukin-1 beta and transforming growth factor-beta-stimulated retinal pigment epithelial cells leads to contraction of collagen gels. Invest Ophthalmol Vis Sci. 1997 Apr. 38(5):824-33. [QxMD MEDLINE Link].
Stocks SZ, Taylor SM, Shiels IA. Transforming growth factor-beta1 induces alpha-smooth muscle actin expression and fibronectin synthesis in cultured human retinal pigment epithelial cells. Clin Experiment Ophthalmol. 2001 Feb. 29(1):33-7. [QxMD MEDLINE Link].
Nassar K, Lüke J, Lüke M, Kamal M, Abd El-Nabi E, Soliman M. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol. 2011 Nov. 249(11):1649-60. [QxMD MEDLINE Link].
Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One. 2008 Jul 16. 3(7):e2675. [QxMD MEDLINE Link]. [Full Text].
Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008 Feb. 92(2):213-6. [QxMD MEDLINE Link].
Arevalo JF, Sanchez JG, Saldarriaga L, Berrocal MH, Fromow-Guerra J, Morales-Canton V. Retinal detachment after bevacizumab. Ophthalmology. 2011 Nov. 118(11):2304.e3-7. [QxMD MEDLINE Link].
Nowak MS, Żurek M, Grabska-Liberek I, Kanclerz P. First Nation-Wide Study of the Incidence and Characteristics of Retinal Detachment in Poland during 2013-2019. J Clin Med. 2023 Feb 12. 12 (4):[QxMD MEDLINE Link].
Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol. 1983 Jan. 95(1):22-33. [QxMD MEDLINE Link].
Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol. 1987 Apr. 105(4):497-502. [QxMD MEDLINE Link].
Williams DF, Williams GA, Hartz A, Mieler WF, Abrams GW, Aaberg TM. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique. Ophthalmology. 1989 Jun. 96(6):752-8. [QxMD MEDLINE Link].
Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998 Oct. 126 (4):550-9. [QxMD MEDLINE Link].
Acar N, Kapran Z, Altan T, Unver YB, Pasaoglu E. Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy. Jpn J Ophthalmol. 2010 Jul. 54 (4):331-7. [QxMD MEDLINE Link].
Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C, et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004 Dec. 111 (12):2240-5. [QxMD MEDLINE Link].
Schiff WM, Hwang JC, Ober MD, Olson JL, Dhrami-Gavazi E, Barile GR, et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol. 2007 Sep. 125 (9):1161-7. [QxMD MEDLINE Link].
Williams RG, Chang S, Comaratta MR, Simoni G. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?. Graefes Arch Clin Exp Ophthalmol. 1996 Aug. 234 (8):496-503. [QxMD MEDLINE Link].
Pastor JC, de la Rúa ER, Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002 Jan. 21 (1):127-44. [QxMD MEDLINE Link].
Amarnani D, Machuca-Parra AI, Wong LL, Marko CK, Stefater JA, Stryjewski TP, et al. Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy. Invest Ophthalmol Vis Sci. 2017 Aug 1. 58 (10):3940-3949. [QxMD MEDLINE Link].
Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD. Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol. 2016. 10:1811-1817. [QxMD MEDLINE Link].
Roca JA, Yon-Mendoza A, Huamán N, Wu L. Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 2021 Oct. 259 (10):2913-2917. [QxMD MEDLINE Link].
Khan MA, Shahlaee A, Toussaint B, Hsu J, Sivalingam A, Dugel PU, et al. Outcomes of 27 Gauge Microincision Vitrectomy Surgery for Posterior Segment Disease. Am J Ophthalmol. 2016 Jan. 161:36-43.e2. [QxMD MEDLINE Link].
Dikopf MS, Patel KH, Setlur VJ, Lim JI. Surgical outcomes of 25-gauge pars plana vitrectomy for diabetic tractional retinal detachment. Eye (Lond). 2015 Sep. 29 (9):1213-9. [QxMD MEDLINE Link].
Berrocal MH. ALL-PROBE VITRECTOMY DISSECTION TECHNIQUES FOR DIABETIC TRACTIONAL RETINAL DETACHMENTS: Lift and Shave. Retina. 2018 Sep. 38 Suppl 1:S2-S4. [QxMD MEDLINE Link].
Cruz-Iñigo YJ, Berrocal MH. Twenty-seven-gauge vitrectomy for combined tractional and rhegmatogenous retinal detachment involving the macula associated with proliferative diabetic retinopathy. Int J Retina Vitreous. 2017. 3:38. [QxMD MEDLINE Link].
Khan MA, Samara WA, Hsu J, Garg S. SHORT-TERM OUTCOMES OF HYBRID 23-, 25-, AND 27-GAUGE VITRECTOMY FOR COMPLEX DIABETIC TRACTIONAL RETINAL DETACHMENT REPAIR. Retin Cases Brief Rep. 2017 Mar 29. [QxMD MEDLINE Link].
Mikhail M, Ali-Ridha A, Chorfi S, Kapusta MA. Long-term outcomes of sutureless 25-G+ pars-plana vitrectomy for the management of diabetic tractional retinal detachment. Graefes Arch Clin Exp Ophthalmol. 2017 Feb. 255 (2):255-261. [QxMD MEDLINE Link].
Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008 Jun. 246(6):837-42. [QxMD MEDLINE Link].
Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008 Feb. 92(2):213-6. [QxMD MEDLINE Link].
Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009 May. 116(5):927-38. [QxMD MEDLINE Link].
da R Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol. 2009 May. 93(5):688-91. [QxMD MEDLINE Link].
Abrams GW, Williams GA. "En bloc" excision of diabetic membranes. Am J Ophthalmol. 1987 Mar 15. 103(3 Pt 1):302-8. [QxMD MEDLINE Link].
Archives of Ophthalmology. Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol. 1992 Jun. 110(6):770-9. [QxMD MEDLINE Link].
Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001 Jul. 108(7):1179-83. [QxMD MEDLINE Link].
Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Luthert PJ, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology. 2001 Jul. 108(7):1184-6. [QxMD MEDLINE Link].
Asaria RH, Kon CH, Bunce C, Sethi CS, Limb GA, Khaw PT, et al. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br J Ophthalmol. 2004 Nov. 88(11):1439-42. [QxMD MEDLINE Link].
Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S. Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol. 2006 Oct. 142(4):636-43. [QxMD MEDLINE Link].
Blumenkranz M, Hernandez E, Ophir A, Norton EW. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology. 1984 Feb. 91(2):122-30. [QxMD MEDLINE Link].
Blumenkranz MS, Hartzer MK, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol. 1987 Mar. 105(3):396-9. [QxMD MEDLINE Link].
Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982 Oct. 94(4):458-67. [QxMD MEDLINE Link].
Campochiaro PA, Glaser BM. Endothelial cells release a chemoattractant for retinal pigment epithelial cells in vitro. Arch Ophthalmol. 1985 Dec. 103(12):1876-80. [QxMD MEDLINE Link].
Campochiaro PA, Glaser BM. Mechanisms involved in retinal pigment epithelial cell chemotaxis. Arch Ophthalmol. 1986 Feb. 104(2):277-80. [QxMD MEDLINE Link].
Campochiaro PA, Glaser BM. Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol. 1985 Apr. 103(4):576-9. [QxMD MEDLINE Link].
Campochiaro PA, Jerdan JA, Glaser BM, Cardin A, Michels RG. Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol. 1985 Sep. 103(9):1403-5. [QxMD MEDLINE Link].
Campochiaro PA, Jerdan JA, Glaser BM, Glaser BM. Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol. 1984 Dec. 102(12):1830-3. [QxMD MEDLINE Link].
Campochiaro PA, Kaden IH, Vidaurri-Leal J, Glaser BM. Cryotherapy enhances intravitreal dispersion of viable retinal pigment epithelial cells. Arch Ophthalmol. 1985 Mar. 103(3):434-6. [QxMD MEDLINE Link].
Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004 Dec. 111(12):2240-5. [QxMD MEDLINE Link].
Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006 Jul-Aug. 26(6):699-700. [QxMD MEDLINE Link].
Clarkson JG, Green WR, Massof D. A histopathologic review of 168 cases of preretinal membrane. Am J Ophthalmol. 1977 Jul. 84(1):1-17. [QxMD MEDLINE Link].
Cusick M, Charles MK, Agrón E, Sangiovanni JP, Ferris FL, Charles S. Anatomical and visual results of vitreoretinal surgery for stage 5 retinopathy of prematurity. Retina. 2006 Sep. 26(7):729-35. [QxMD MEDLINE Link].
de Juan E Jr, Sternberg P Jr, Michels RG. Timing of vitrectomy after penetrating ocular injuries. Ophthalmology. 1984 Sep. 91(9):1072-4. [QxMD MEDLINE Link].
Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology. 1987 Apr. 94(4):327-32. [QxMD MEDLINE Link].
Glaser BM, Vidaurri-Leal J, Michels RG, Campochiaro PA. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology. 1993 Apr. 100(4):466-70. [QxMD MEDLINE Link].
Greven C, Tasman W. Scleral buckling in stages 4B and 5 retinopathy of prematurity. Ophthalmology. 1990 Jun. 97(6):817-20. [QxMD MEDLINE Link].
Hsu HT, Ryan SJ. Experimental retinal detachment in the rabbit. Penetrating ocular injury with retinal laceration. Retina. 1986 Winter-Spring. 6(1):66-9. [QxMD MEDLINE Link].
Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS. Inhibition of intraocular fibrin formation following infusion of low- molecular-weight heparin during vitrectomy. Arch Ophthalmol. 1991 Mar. 109(3):405-9. [QxMD MEDLINE Link].
Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991. 229(5):464-7. [QxMD MEDLINE Link].
Kirchhof B. Strategies to influence PVR development. Graefes Arch Clin Exp Ophthalmol. 2004 Aug. 242(8):699-703. [QxMD MEDLINE Link].
Kirmani M, Ryan SJ. In vitro measurement of contractile force of transvitreal membranes formed after penetrating ocular injury. Arch Ophthalmol. 1985 Jan. 103(1):107-10. [QxMD MEDLINE Link].
Lakhanpal RR, Fortun JA, Chan-Kai B, Holz ER. Lensectomy and vitrectomy with and without intravitreal triamcinolone acetonide for vascularly active stage 5 retinal detachments in retinopathy of prematurity. Retina. 2006 Sep. 26(7):736-40. [QxMD MEDLINE Link].
Maguire AM, Trese MT. Lens-sparing vitreoretinal surgery in infants. Arch Ophthalmol. 1992 Feb. 110(2):284-6. [QxMD MEDLINE Link].
Meredith TA, Kaplan HJ, Aaberg TM. Pars plana vitrectomy techniques for relief of epiretinal traction by membrane segmentation. Am J Ophthalmol. 1980 Mar. 89(3):408-13. [QxMD MEDLINE Link].
Michels RG. Proliferative diabetic retinopathy: Pathophysiology of extraretinal complications and principles of vitreous surgery. Retina. 1981. 1:1-17.
Miller B, Miller H, Patterson R, Ryan SJ. Retinal wound healing. Cellular activity at the vitreoretinal interface. Arch Ophthalmol. 1986 Feb. 104(2):281-5. [QxMD MEDLINE Link].
Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002 Jan. 21(1):127-44. [QxMD MEDLINE Link].
Quinn GE, Dobson V, Barr CC, Davis BR, Flynn JT, Palmer EA, et al. Visual acuity in infants after vitrectomy for severe retinopathy of prematurity. Ophthalmology. 1991 Jan. 98(1):5-13. [QxMD MEDLINE Link].
Rachal WF, Burton TC. Changing concepts of failures after retinal detachment surgery. Arch Ophthalmol. 1979 Mar. 97(3):480-3. [QxMD MEDLINE Link].
Schrey S, Krepler K, Wedrich A. Incidence of rhegmatogenous retinal detachment after vitrectomy in eyes of diabetic patients. Retina. 2006 Feb. 26(2):149-52. [QxMD MEDLINE Link].
Singh AK, Michels RG, Glaser BM. Scleral indentation following cryotherapy and repeat cryotherapy enhance release of viable retinal pigment epithelial cells. Retina. 1986 Summer-Fall. 6(3):176-8. [QxMD MEDLINE Link].
Stern WH, Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK, et al. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol. 1983 Jul. 96(1):33-42. [QxMD MEDLINE Link].
Sun JK, Arroyo JG. Adjunctive therapies for proliferative vitreoretinopathy. Int Ophthalmol Clin. 2004. 44(3):1-10. [QxMD MEDLINE Link].
Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980 Jan. 89(1):131-6. [QxMD MEDLINE Link].
Trese MT. Visual results and prognostic factors for vision following surgery for stage V retinopathy of prematurity. Ophthalmology. 1986 May. 93(5):574-9. [QxMD MEDLINE Link].
Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol. 2004 Jun. 137(6):1105-15. [QxMD MEDLINE Link].
Ussmann JH, Lazarides E, Ryan SJ. Traction retinal detachment. A cell-mediated event. Arch Ophthalmol. 1981 May. 99(5):869-72. [QxMD MEDLINE Link].
Vidaurri-Leal J, Hohman R, Glaser BM. Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells. A new approach to the study of proliferative vitreoretinopathy. Arch Ophthalmol. 1984 Aug. 102(8):1220-3. [QxMD MEDLINE Link].
Vidaurri-Leal JS, Glaser BM. Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells. Arch Ophthalmol. 1984 Sep. 102(9):1376-9. [QxMD MEDLINE Link].
Weiss JF, Belkin M. The effect of penicillamine on posttraumatic vitreous proliferation. Am J Ophthalmol. 1981 Nov. 92(5):625-7. [QxMD MEDLINE Link].
Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007 Apr. 114(4):698-704. [QxMD MEDLINE Link].
Wiedemann P, Lemmen K, Schmiedl R, Heimann K. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol. 1987 Jul 15. 104(1):10-4. [QxMD MEDLINE Link].
Yeo JH, Sadeghi J, Campochiaro PA, Green WR, Glaser BM. Intravitreous fibronectin and platelet-derived growth factor. New model for traction retinal detachment. Arch Ophthalmol. 1986 Mar. 104(3):417-21. [QxMD MEDLINE Link].
Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol. 2008 Jul. 36(5):449-54. [QxMD MEDLINE Link].